Beckman Coulter secures EUA for SARS-CoV-2 test

By LabPulse.com staff writers

June 29, 2020 -- Beckman Coulter has secured an emergency use authorization (EUA) from the U.S. Food and Drug Administration for its SARS-CoV-2 immunoglobulin G antibody test.

The company said that is able to offer 30 million tests per month in all countries that accept the EUA and the CE Mark, and has already distributed tests to 400 hospitals, clinics, and laboratories in the U.S. The test, which targets antibodies that recognize the receptor binding domain of the spike protein that SARS-CoV-2 uses to bind to a human cell receptor, has 100% sensitivity and 99.6% specificity, according to the firm.

Beckman Coulter's SARS-CoV-2 IgG assay hits CE Mark countries
Beckman Coulter announced its Access SARS-CoV-2 immunoglobulin G (IgG) assay is now available in markets that accept the CE Mark.
Beckman Coulter debuts new tabletop hematology analyzer
Beckman Coulter has launched its DxH 690T tabletop hematology analyzer in the U.S.
Beckman Coulter to release IgG serology test
Beckman Coulter is targeting mid-May for the launch of its new Access SARS-CoV-2 immunoglobulin G (IgG) serology test.
Beckman Coulter floats Access PCT sepsis test in U.S.
Beckman Coulter announced on January 28 that its Access PCT procalcitonin assay is available in the U.S. as a test cleared by the U.S. Food and Drug Administration.
Beckman Coulter launches DxA 5000 for lab automation in U.S.
Beckman Coulter's DxA 5000 lab automation system has received 510(k) clearance from the U.S. Food and Drug Administration and is now available.

Copyright © 2020 LabPulse.com

Last Updated eh 6/29/2020 11:13:19 AM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email